Crossover Study From Macitentan or Bosentan Over to Ambrisentan
Status:
Terminated
Trial end date:
2017-07-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about the safety and effects of switching
treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24
weeks in subjects with Connective Tissue Disease associated Pulmonary Arterial Hypertension
(CTD-PAH).